Thermo Fisher Scientific HCAR2/HCAR3 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:1,000-1:3,000

-

Immunocytochemistry (ICC/IF)

1:100-1:500

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

A synthesized peptide derived from human HCAR2(Accession Q8TDS4), corresponding to amino acid residues F304-S354. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:HCAR2/HCAR3,uniProtId:Q8TDS4-1,ncbiNodeId:9606,antigenRange:304-354|363,antigenLength:363,antigenImageFileName:PA5-99937_HCAR2HCAR3_Q8TDS4-1_Rabbit.svg,antigenImageFileNamePDP:PA5-99937_HCAR2HCAR3_Q8TDS4-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Affinity chromatography

Storage buffer

PBS, pH 7.4, with 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Wet ice

RRID

AB_2818870

Product Specific Information

Antibody detects endogenous levels of total GPR109A/B.

Target Information

Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.